Finally, in translational medicine, multiple preclinical studies have provided clear therapeutic doses and safety windows, such as PLGA-Mdivi1 nanoneedles reducing myocardial infarction area in mice, AAV2-PINK1 rescuing dopaminergic neurons in primate PD models, and Ligustrazine nano-drug delivery systems targeting the PIEZO1-PHB2 axis to protect cardiomyocyte mitochondria. This evidence concerns the gene PHB2 and myocardial infarction.